Biokinetic modelling of DTPA decorporation therapy: the CONRAD approach.

Administration of diethylene triamine pentaacetic acid (DTPA) can enhance the urinary excretion rate of plutonium (Pu) for several days, but most of this Pu decorporation occurs on the first day after treatment. The development of a biokinetic model describing the mechanisms of decorporation of actinides by administration of DTPA was initiated as a task of the coordinated network for radiation dosimetry project. The modelling process was started by using the systemic biokinetic model for Pu from Leggett et al. and the biokinetic model for DTPA compounds of International Commission on Radiation Protection Publication 53. The chelation of Pu and DTPA to Pu-DTPA was treated explicitly and is assumed to follow a second-order process. It was assumed that the chelation takes place in the blood and in the rapid turnover soft tissues compartments of the Pu model, and that Pu-DTPA behaves in the same way as administered DTPA. First applications of this draft model showed that the height of the peak of urinary excretion after administration of DTPA was determined by the chelation rate. However, repetitions of DTPA administration shortly after the first one showed no effect in the application of the draft model in contrast to data from real cases. The present draft model is thus not yet realistic. Therefore several questions still have to be answered, notably about where the Pu-DTPA complexes are formed, which biological ligands of Pu are dissociated, if Pu-DTPA is stable and if the biokinetics of Pu-DTPA excretion is similar to that of DTPA. Further detailed studies of human contamination cases and experimental data about Pu-DTPA kinetics will be needed in order to address these issues. The work will now be continued within a working group of EURADOS.

[1]  J. Poncy,et al.  In Vitro and In Vivo Assessment of Plutonium Speciation and Decorporation in Blood and Target Retention Tissues after a Systemic Contamination followed by an Early Treatment with DTPA , 2008, Radiation research.

[2]  T. Pellmar.  Development of a Biokinetic Model for Radionuclide-Contaminated Wounds and Procedures for Their Assessment, Dosimetry and Treatment , 2008 .

[3]  A. Sérandour,et al.  Pulmonary retention of actinides after dissolution of PuO2aerosols : interest in modelling DTPA decorporation , 2008 .

[4]  E Blanchardon,et al.  The work of the CONRAD task group 5.2: research studies on biokinetic models. , 2007, Radiation protection dosimetry.

[5]  P. Battisti,et al.  Coordination of research on internal dosimetry in Europe: the CONRAD project. , 2007, Radiation Protection Dosimetry.

[6]  P. Fritsch,et al.  Modelling of bioassay data from a Pu wound treated by repeated DTPA perfusions: biokinetics and dosimetric approaches. , 2007, Radiation protection dosimetry.

[7]  P. Bérard,et al.  Treatment of actinide exposures: a review of Ca-DTPA injections inside CEA-COGEMA plants. , 2007, Radiation protection dosimetry.

[8]  E. H. Carbaugh,et al.  Ustur whole body case 0269: demonstrating effectiveness of i.v. CA-DTPA for Pu. , 2007, Radiation protection dosimetry.

[9]  E Blanchardon,et al.  IDEAS internal contamination database: a compilation of published internal contamination cases. A tool for the internal dosimetry community. , 2006, Radiation protection dosimetry.

[10]  E. Fattal,et al.  Predicting Plutonium Decorporation Efficacy after Intravenous Administration of DTPA Formulations: Study of Pharmacokinetic–Pharmacodynamic Relationships in Rats , 2006, Pharmaceutical Research.

[11]  J. Valentin,et al.  Human Alimentary Tract Model for Radiological Protection , 2006 .

[12]  R. Leggett,et al.  Mayak Worker Study: An Improved Biokinetic Model for Reconstructing Doses from Internally Deposited Plutonium , 2005, Radiation research.

[13]  D. Taylor,et al.  Treatment of accidental intakes of plutonium and americium: guidance notes. , 2005, Applied radiation and isotopes : including data, instrumentation and methods for use in agriculture, industry and medicine.

[14]  E. Fattal,et al.  Targeting of diethylene triamine pentaacetic acid encapsulated in liposomes to rat liver: an effective strategy to prevent bone deposition and increase urine elimination of plutonium in rats , 2004, International journal of radiation biology.

[15]  A. Miele,et al.  Implications du médecin du travail et de l'expert dans la gestion et la dosimétrie d'un incident de contamination : exemple d'une plaie contaminée par le plutonium , 2003 .

[16]  A. Luciani,et al.  Verification and modification of the ICRP-67 model for plutonium dose calculation. , 2000, Health physics.

[17]  P. Gourmelon,et al.  Decorporation Treatment - Medical Overview , 2000 .

[18]  T. LaBone.  Evaluation of intakes of transuranics influenced by chelation therapy , 1994 .

[19]  Icrp.  Human Respiratory Tract Model for Radiological Protection , 1994 .

[20]  H. Doerfel,et al.  Incorporation of 241Am: Effectiveness of Late DTPA Chelation Therapy , 1989 .

[21]  Icrp.  Radiation dose to patients from radiopharmaceuticals , 1988 .

[22]  M. Bailey,et al.  The retention of 14C-DTPA in human volunteers after inhalation or intravenous injection. , 1983, Health physics.

[23]  M. Bhattacharyya,et al.  Action of DTPA on hepatic plutonium. III. Evidence for a direct chelation mechanism for DTPA-induced excretion of monomeric plutonium into rat bile. , 1979, Radiation research.

[24]  W Stevens,et al.  The retention and distribution of 241Am and 65Zn, given as DTPA chelates in rats and of [14C]DTPA in rats and beagles. , 1978, Radiation research.

[25]  F. Chao,et al.  Estimation of skeletal plutonium levels based on DPTA-induced radionuclide excretion in feces: possible application to man. , 1978, Health Physics.

[26]  Smith Ja,et al.  A mathematical model for estimation of plutonium in the human body from urine data influenced by DTPA therapy. , 1978 .

[27]  J. Lynn,et al.  Assessment and management of a plutonium contaminated wound case. , 1974, Health physics.

[28]  G. Poda,et al.  Treatment and evaluation of a plutonium-238 nitrate contaminated puncture wound. A two-year case history. , 1972, Health physics.

[29]  K. Heid,et al.  Interpretation of human urinary excretion of plutonium for cases treated with DTPA. , 1972, Health physics.

[30]  D. W. Baxter,et al.  Gastrointestinal absorption and retention of plutonium chelates. , 1972, Health Physics.

[31]  S. Kety.  THE LEAD CITRATE COMPLEX ION AND ITS RÔLE IN THE PHYSIOLOGY AND THERAPY OF LEAD POISONING , 1942 .